Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Cancer Drug Developer NewLink Genetics Gets Push From Analysts


However, proof of success for the company's immune system-boosting treatment is at least a year away.

Can the next big thing in cancer treatment come from Ames, Iowa?

Newly public biotech company NewLink Genetics (NLNK) is developing treatments that help the immune system fight cancer. Its lead product candidate is an injected drug for pancreatic cancer, a very deadly disease with poor choices for treatment. The drug is being tested in the last of three phases of study usually needed for US approval but significant stock-moving events may be at least a year away.

After the company's initial public offering last month, analysts from four firms Wednesday initiated coverage with buy recommendations. It should be noted all four firms (Canaccord Genuity, Cantor Fitzgerald, Robert W. Baird and Stifel Nicolaus) were involved in the company's IPO.

In a little more than a month of trading, NewLink's stock dropped about 1%, trading at $7 a share early afternoon Wednesday. The 12-month analyst target prices range from $10 to $16 a share.

"Given the high risk, high reward nature of this story, we would not necessarily advise a focused exposure here, but do think it makes a good addition to any aggressive growth-oriented portfolio," Baird analyst Christopher Raymond says. He has a $10 target for the stock.

So-called immunotherapies are generating a lot of interest in the medical and financial communities and are at the center of two of the more interesting plot lines this year for biotech investors. Dendreon's (DNDN) Provenge vaccine for prostate cancer was hailed as a revolutionary treatment but sales proved to be disappointing. (See Dendreon's Stock Plunges on Low Provenge Sales.) On the other hand, Bristol-Myers Squibb (BMY) benefited from a strong sales launch of the melanoma treatment Yervoy.

NewLink's therapy uses genetically modified human cells to help trigger the body's immune system and fight cancer. In early studies, high doses of the treatment extended patients' lives by a year. But results of the larger study being conducted now (about 700 patients) will give investors a better sense of whether NewLink has a viable product.

Expect some study data in late 2012 or early 2013, says Chief Financial Officer Gordon Link.

"Their technology and approach is sound, but only time will tell," says biotech industry analyst Michael Becker.

As for the company's location amid the cornfields of Iowa, Link admits "it's not a hotbed for biotech." And Raymond notes that some investors may be put off by the company's location since it's not based in either of the biotechnogly hubs of California or Massachusetts.

But, in the end, the data will determine the company's fortunes.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos